Mupirocin
Bactroban, Centany (mupirocin) is a small molecule pharmaceutical. Mupirocin was first approved as Bactroban on 1987-12-31. It is used to treat bacterial infections and impetigo in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Centany (generic drugs available since 2003-11-07, discontinued: Bactroban)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| impetigo | EFO_1000714 | D007169 | L01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX09: Mupirocin
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AX: Other nasal preparations in atc
— R01AX06: Mupirocin
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | 4 | 5 | 9 | |
| Surgical wound infection | D013530 | — | — | 1 | 3 | 4 | 8 | ||
| Staphylococcal infections | D013203 | A49.01 | — | 1 | — | 5 | 1 | 7 | |
| Methicillin-resistant staphylococcus aureus | D055624 | — | 1 | — | 2 | 3 | 6 | ||
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | — | — | 1 | 3 | 4 |
| Microbiota | D064307 | — | — | — | 2 | — | 2 | ||
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 2 | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | 1 | 2 |
| Orthopedic procedures | D019637 | — | — | — | 1 | — | 1 | ||
| Bacterial infections | D001424 | A49 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Impetigo | D007169 | EFO_1000714 | L01 | 1 | 1 | 1 | — | 1 | 4 |
| Radiodermatitis | D011855 | L58 | — | 1 | 1 | — | — | 1 | |
| Hereditary hemorrhagic telangiectasia | D013683 | I78.0 | — | — | 1 | — | — | 1 | |
| Epistaxis | D004844 | EFO_0003895 | R04.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 3 | — | — | — | 3 |
| Staphylococcus | D013210 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Abscess | D000038 | EFO_0003030 | — | — | — | — | 4 | 4 | |
| Furunculosis | D005667 | L02.92 | — | — | — | — | 3 | 3 | |
| Musculoskeletal diseases | D009140 | — | — | — | — | 1 | 1 | ||
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 | |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | — | — | — | 1 | 1 |
| Cesarean section | D002585 | — | — | — | — | 1 | 1 | ||
| Endophthalmitis | D009877 | — | — | — | — | 1 | 1 | ||
| Community-acquired infections | D017714 | — | — | — | — | 1 | 1 | ||
| Folliculitis | D005499 | — | — | — | — | 1 | 1 | ||
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MUPIROCIN |
| INN | mupirocin |
| Description | Mupirocin is an alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections. It has a role as a bacterial metabolite, an antibacterial drug and a protein synthesis inhibitor. It is a monocarboxylic acid, a member of oxanes, an epoxide, a secondary alcohol, a triol and an alpha,beta-unsaturated carboxylic ester. It is a conjugate acid of a mupirocin(1-). |
| Classification | Small molecule |
| Drug class | t-RNA synthetase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 12650-69-0 |
| RxCUI | 42372 |
| ChEMBL ID | CHEMBL719 |
| ChEBI ID | 7025 |
| PubChem CID | 446596 |
| DrugBank | DB00410 |
| UNII ID | D0GX863OA5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,727 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
51,720 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more